Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 27,881,484
  • Shares Outstanding, K 204,770
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104,220 K
  • 36-Month Beta 0.90
  • Price/Sales 24.90
  • Price/Cash Flow 143.82
  • Price/Book 28.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.03 +20.88%
on 05/15/17
138.75 -0.66%
on 05/24/17
+13.93 (+11.24%)
since 04/24/17
3-Month
114.03 +20.88%
on 05/15/17
153.15 -10.00%
on 03/15/17
+6.63 (+5.05%)
since 02/24/17
52-Week
71.75 +92.11%
on 06/27/16
153.15 -10.00%
on 03/15/17
+56.57 (+69.61%)
since 05/24/16

Most Recent Stories

More News
Incyte to Present at Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:

INCY : 137.86 (+1.25%)
After Yesterday's Rally of 2.01% Shares Could Potentially Pullback

Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $130.22 to a high of $134.55. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $133.80...

INCY : 137.86 (+1.25%)
Company News for May 19, 2017

Companies in the News are: LB,P,INCY,MRK,SHPG

P : 9.20 (+0.66%)
LB : 49.61 (-1.08%)
MRK : 64.95 (+0.62%)
INCY : 137.86 (+1.25%)
SHPG : 185.08 (+0.05%)
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor

Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).

VVUS : 1.09 (-2.68%)
MRK : 64.95 (+0.62%)
INCY : 137.86 (+1.25%)
BMY : 53.78 (-0.79%)
Wal-Mart Stores, Pandora rise; Ascena Retail, Alibaba fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

CSCO : 31.42 (-1.07%)
LB : 49.61 (-1.08%)
FLO : 18.67 (+0.59%)
INCY : 137.86 (+1.25%)
RL : 66.52 (-1.74%)
SIRI : 5.11 (+2.82%)
ASNA : 1.88 (-2.08%)
Concert Pharma Falls After Clinical Hold on Hair Loss Drug

Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543...

CNCE : 14.31 (+1.92%)
VVUS : 1.09 (-2.68%)
VRTX : 118.01 (+1.22%)
INCY : 137.86 (+1.25%)
First Data from Combination of Epacadostat with Opdivo(R) (nivolumab) Will Be Highlighted at ASCO 2017

Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and...

INCY : 137.86 (+1.25%)
New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda(R) (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination...

MRK : 64.95 (+0.62%)
INCY : 137.86 (+1.25%)
Incyte Falls 1.04% on Heavy Volume: Watch For Potential Rebound

Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $114.33 to a high of $117.86. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $116.21...

INCY : 137.86 (+1.25%)
After Yesterday's Decline of 1.04%, Incyte Offers Investors Better Value

Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $114.33 to a high of $117.86. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $116.21...

INCY : 137.86 (+1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 138.11
1st Resistance Point 137.14
Last Price 137.86
1st Support Level 134.35
2nd Support Level 132.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.